Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Organon & Co. Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $40.01 (market cap $139.69M), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 25.8× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 62 Days and Organon & Co. Common Stock for 0 Days on average.
| GPTY | OGN | |
|---|---|---|
Market Cap | $139.69M | $3.61B |
Volume | 81,745 | 1,808,049 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $13.81 |
52-Week Low | $34.73 | $5.70 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY, a US stock, trades at $42.44, up 0.05% in the last 24 hours. The technical outlook is bearish based on moving averages, with key support at $42 and resistance at $43. Recent news highlights the ETF's weekly dividend distributions and a Seeking Alpha article from August 2026 rating it a Buy for high AI-driven income, citing its covered call spread strategy.
The outlook for GPTY is mixed, with a high-yield income opportunity from consistent dividends but tempered by bearish technical signals and limited fundamental data. Risks include market volatility and dependence on options strategies, while institutional interest remains a potential catalyst.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
